\n| Free chlorine<\/td>\n | Disinfection drop after PFAS treatment barrier<\/td>\n | Residual Chlorine Transmitter<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n A monitoring architecture built around these three surrogates, deployed at influent, mid-treatment, and finished water positions, provides 24\/7 visibility into whether the PFAS treatment process is operating as designed.<\/p>\n Shanghai ChiMay<\/strong> sensors configured for this architecture share Modbus register maps, calibration documentation standards, and SCADA integration patterns, which simplifies the data infrastructure underlying the compliance risk model.<\/p>\n<\/span>Building the 2029 Budget Compliance Risk Model<\/span><\/h2>\nA defensible compliance risk model for the 2029 budget cycle includes four scenario layers:<\/p>\n <\/span>Scenario 1: Baseline Compliance<\/span><\/h3>\nTreatment process operates within design parameters; all surrogate monitoring stays inside alarm bands; PFOA results remain below 4 ppt. Budget impact: routine O&M, planned bed change, scheduled sensor calibration.<\/p>\n <\/span>Scenario 2: Surrogate Excursion, No Exceedance<\/span><\/h3>\nSurrogate monitoring detects a treatment process anomaly (rising effluent conductivity, breakthrough turbidity); operators respond with bed change, lead-lag swap, or process adjustment; PFOA results remain below 4 ppt. Budget impact: unplanned treatment intervention but no compliance event.<\/p>\n <\/span>Scenario 3: Single PFOA Exceedance<\/span><\/h3>\nA single quarterly sample reports PFOA above 4 ppt; running annual average remains compliant; utility executes follow-up sampling and root cause analysis. Budget impact: increased sampling frequency, technical investigation, possible treatment process upgrade.<\/p>\n <\/span>Scenario 4: Running Annual Average Exceedance<\/span><\/h3>\nQuarterly running average exceeds 4 ppt; Tier 2 public notification is triggered; state agency review begins; capital project may be required. Budget impact: legal, public communication, potential capital project, customer notification.<\/p>\n The model assigns probability weights to each scenario based on treatment process maturity, sampling history, and surrogate monitoring coverage. The output is an expected-value risk number that supports budget allocation across monitoring, treatment, legal, and communication line items.<\/p>\n <\/span>How Surrogate Monitoring Shifts the Probability Distribution<\/span><\/h2>\nThe fundamental financial argument for continuous surrogate monitoring is that it shifts probability mass from Scenarios 3 and 4 toward Scenarios 1 and 2. Operators who detect treatment process degradation through surrogate parameters in real time can execute corrective action before laboratory PFAS results report an exceedance.<\/p>\n A simplified before-and-after probability profile might look like:<\/p>\n \n\n\n| Scenario<\/th>\n | Without Surrogate Monitoring<\/th>\n | With Surrogate Monitoring<\/th>\n<\/tr>\n<\/thead>\n | \n\n| 1: Baseline<\/td>\n | 70%<\/td>\n | 78%<\/td>\n<\/tr>\n | \n| 2: Surrogate excursion<\/td>\n | 15%<\/td>\n | 18%<\/td>\n<\/tr>\n | \n| 3: Single exceedance<\/td>\n | 12%<\/td>\n | 3%<\/td>\n<\/tr>\n | \n| 4: Annual average exceedance<\/td>\n | 3%<\/td>\n | 1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n The shift looks modest in percentage terms but produces large financial reductions because Scenarios 3 and 4 carry the largest cost tails. Even a 75% reduction in Scenario 4 probability can offset the full CAPEX of the surrogate monitoring suite within a single budget cycle.<\/p>\n <\/span>Vendor Consolidation in the Risk Model<\/span><\/h2>\nThe compliance risk model is sensitive to data quality. Fragmented sensor portfolios \u2014 different vendors at different process positions, inconsistent calibration documentation, mismatched Modbus register maps \u2014 produce noise that erodes the leading-indicator value of surrogate monitoring.<\/p>\n Shanghai ChiMay<\/strong> sensors deployed across the PFAS treatment train provide:<\/p>\n | |